There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cellectar Biosciences (CLRB – Research Report), Ionis Pharmaceuticals (IONS – Research Report) and CVRx (CVRX – Research Report) with bullish sentiments.
Cellectar Biosciences (CLRB)
In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Cellectar Biosciences, with a price target of $11.00. The company’s shares closed last Monday at $3.64, close to its 52-week high of $3.80.
According to TipRanks.com, Jones is a 1-star analyst with an average return of
Currently, the analyst consensus on Cellectar Biosciences is a Moderate Buy with an average price target of $9.00, which is a 153.5% upside from current levels. In a report issued on January 9, Maxim Group also assigned a Buy rating to the stock with a $7.00 price target.
See today’s best-performing stocks on TipRanks >>
Ionis Pharmaceuticals (IONS)
Needham analyst Joseph Stringer maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $60.00. The company’s shares closed last Monday at $51.47, close to its 52-week high of $54.44.
According to TipRanks.com, Stringer is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ionis Pharmaceuticals with a $55.71 average price target, representing an 8.7% upside. In a report issued on January 8, Wells Fargo also maintained a Buy rating on the stock with a $85.00 price target.
CVRx (CVRX)
In a report released today, Alexander Nowak from Craig-Hallum assigned a Buy rating to CVRx. The company’s shares closed last Monday at $26.55.
According to TipRanks.com, Nowak is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CVRx with a $29.50 average price target, implying a 9.2% upside from current levels. In a report issued on January 8, Canaccord Genuity also maintained a Buy rating on the stock with a $30.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CLRB:
- Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
- Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
- Cellectar announces preclinical data for CLR 121225
- Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
- Biotech Alert: Searches spiking for these stocks today
